Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
How might diet alleviate lipitor's liver impact?How often should lurbinectedin's long term effects be monitored?How many years does kadcyla's market exclusivity last?Guselkumab patent expiration?Patent tenofovir alafenamide gilead?
See the DrugPatentWatch profile for Nusinersen
Nusinersen (Spinraza) received its European Medicines Agency (EMA) orphan designation on 20 June 2012. [1]
EMA orphan designation is granted for medicines intended to treat, prevent, or diagnose rare diseases in the EU. The designation date is the date EMA records the medicine as eligible for orphan status, separate from the later date of marketing authorization. [1]
You can confirm the date in EMA’s product/orphan designation information using the Spinraza (nusinersen) entry shown in the source record. [1] Sources: [1] https://www.ema.europa.eu/en/medicines/orphan-designations/eu-orphan-designations-database/nusinersen
Other Questions About Nusinersen :